Atossa Therapeutics Inc
Atossa Therapeutics Inc (ATOS) Historical Volatility
ATOS's 30 day historical volatility is 82.22%, in the 58th percentile of readings over the past year. This is an average percentile, meaning Atossa Therapeutics Inc shares have moved roughly in line with their typical range. ATOS's 30 day implied volatility sits at 193.72%, with an IV Rank of 65.48%, leaving IV 111.50 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking ATOS historical volatility helps you see how much Atossa Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ATOS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ATOS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ATOS's 30 day historical volatility, or ATOS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ATOS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →